Cargando…

Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study

AIM OF THE STUDY: Ongoing national screening programmes suggest that the prevalence of chronic hepatitis C (CHC) in Poland ranges between 0.5% and 1%. It has been recently noted that patients with confirmed coronary artery disease may be at higher risk for hepatitis C virus (HCV) infection. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Piekarska, Anna, Mamzer-Dachnowska, Aleksandra, Kasprzak, Jarosław D., Peruga, Jan Z., Kaszuba, Andrzej, Berkan-Kawińska, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728861/
https://www.ncbi.nlm.nih.gov/pubmed/31501787
http://dx.doi.org/10.5114/ceh.2019.84782
_version_ 1783449494287810560
author Piekarska, Anna
Mamzer-Dachnowska, Aleksandra
Kasprzak, Jarosław D.
Peruga, Jan Z.
Kaszuba, Andrzej
Berkan-Kawińska, Aleksandra
author_facet Piekarska, Anna
Mamzer-Dachnowska, Aleksandra
Kasprzak, Jarosław D.
Peruga, Jan Z.
Kaszuba, Andrzej
Berkan-Kawińska, Aleksandra
author_sort Piekarska, Anna
collection PubMed
description AIM OF THE STUDY: Ongoing national screening programmes suggest that the prevalence of chronic hepatitis C (CHC) in Poland ranges between 0.5% and 1%. It has been recently noted that patients with confirmed coronary artery disease may be at higher risk for hepatitis C virus (HCV) infection. MATERIAL AND METHODS: Testing for the presence of anti-HCV antibodies was performed in a group of patients admitted to the Cardiology Department with symptomatic ischemic heart disease (IHD) and in patients hospitalised in the Dermatology Department. RESULTS: A total of 1171 patients underwent anti-HCV testing: 672 patients in the Cardiology Department (K group) and 499 patients in the Dermatology Department (D group). Twenty-eight (2.4%) positive anti-HCV results were detected. The prevalence of positive anti-HCV antibodies in groups K and D was 2.23% and 2.61%, respectively (p > 0.05). Presence of HCV RNA was confirmed in 15 cases (1.28%) – 7 patients in group K and 8 patients in group D (1.04% and 1.6%, respectively; p > 0.05). CONCLUSIONS: Our findings suggest that this patient cohort has increased risk of HCV infection, which may influence screening strategies.
format Online
Article
Text
id pubmed-6728861
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-67288612019-09-09 Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study Piekarska, Anna Mamzer-Dachnowska, Aleksandra Kasprzak, Jarosław D. Peruga, Jan Z. Kaszuba, Andrzej Berkan-Kawińska, Aleksandra Clin Exp Hepatol Original Paper AIM OF THE STUDY: Ongoing national screening programmes suggest that the prevalence of chronic hepatitis C (CHC) in Poland ranges between 0.5% and 1%. It has been recently noted that patients with confirmed coronary artery disease may be at higher risk for hepatitis C virus (HCV) infection. MATERIAL AND METHODS: Testing for the presence of anti-HCV antibodies was performed in a group of patients admitted to the Cardiology Department with symptomatic ischemic heart disease (IHD) and in patients hospitalised in the Dermatology Department. RESULTS: A total of 1171 patients underwent anti-HCV testing: 672 patients in the Cardiology Department (K group) and 499 patients in the Dermatology Department (D group). Twenty-eight (2.4%) positive anti-HCV results were detected. The prevalence of positive anti-HCV antibodies in groups K and D was 2.23% and 2.61%, respectively (p > 0.05). Presence of HCV RNA was confirmed in 15 cases (1.28%) – 7 patients in group K and 8 patients in group D (1.04% and 1.6%, respectively; p > 0.05). CONCLUSIONS: Our findings suggest that this patient cohort has increased risk of HCV infection, which may influence screening strategies. Termedia Publishing House 2019-04-30 2019-05 /pmc/articles/PMC6728861/ /pubmed/31501787 http://dx.doi.org/10.5114/ceh.2019.84782 Text en Copyright: © 2019 Clinical and Experimental Hepatology http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Piekarska, Anna
Mamzer-Dachnowska, Aleksandra
Kasprzak, Jarosław D.
Peruga, Jan Z.
Kaszuba, Andrzej
Berkan-Kawińska, Aleksandra
Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study
title Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study
title_full Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study
title_fullStr Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study
title_full_unstemmed Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study
title_short Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study
title_sort prevalence of hepatitis c virus infection in patients hospitalised for ischemic heart disease versus controls – pro-cardio-c study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728861/
https://www.ncbi.nlm.nih.gov/pubmed/31501787
http://dx.doi.org/10.5114/ceh.2019.84782
work_keys_str_mv AT piekarskaanna prevalenceofhepatitiscvirusinfectioninpatientshospitalisedforischemicheartdiseaseversuscontrolsprocardiocstudy
AT mamzerdachnowskaaleksandra prevalenceofhepatitiscvirusinfectioninpatientshospitalisedforischemicheartdiseaseversuscontrolsprocardiocstudy
AT kasprzakjarosławd prevalenceofhepatitiscvirusinfectioninpatientshospitalisedforischemicheartdiseaseversuscontrolsprocardiocstudy
AT perugajanz prevalenceofhepatitiscvirusinfectioninpatientshospitalisedforischemicheartdiseaseversuscontrolsprocardiocstudy
AT kaszubaandrzej prevalenceofhepatitiscvirusinfectioninpatientshospitalisedforischemicheartdiseaseversuscontrolsprocardiocstudy
AT berkankawinskaaleksandra prevalenceofhepatitiscvirusinfectioninpatientshospitalisedforischemicheartdiseaseversuscontrolsprocardiocstudy